Recombinant Human LOX1 Protein
Beta LifeScience
SKU/CAT #: BLK-01731P-100UG

Human LOX1 on Tris-Bis PAGE under reduced condition and Non reducing (N) condition. The purity is greater than 95%.
Recombinant Human LOX1 Protein
Beta LifeScience
SKU/CAT #: BLK-01731P-100UG
Collections: High-quality recombinant proteins, Other recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human LOX1 Protein is expressed from HEK293 with His tag at the N-Terminus.It contains Ser61-Gln273. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | P78380 |
Target Symbol | LOX1 |
Synonyms | Ox-LDL receptor 1; LOX-1; CLEC8A; LOX1; OLR1; LOXIN; SR-E1; SCARE1; SLOX1 |
Species | Human |
Expression System | HEK293 |
Tag | N-His |
Expression Range | Ser61-Gln273 |
Mol. Weight | The protein has a predicted MW of 25.4 kDa. Due to glycosylation, the protein migrates to 30-36 kDa under reduced condition and 60-70 kDa under Non reducing (N) condition based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | LOX-1 is a transmembrane glycoprotein that binds to and internalizes ox-LDL.LOX-1 gene deletion in mice and anti-LOX-1 therapy has been shown to decrease inflammation, oxidative stress and atherosclerosis. LOX-1 deletion also results in damage from ischemia, making LOX-1 a promising target of therapy for atherosclerosis and related disorders. In this article we focus on the different mechanisms for regulation, signaling and the various effects of LOX-1 in contributing to atherosclerosis. |